AI assistant
Sending…
Compass Therapeutics, Inc. — Director's Dealing 2025
Feb 13, 2025
32588_dirs_2025-02-13_cda33f13-14f0-45f3-b4e0-d83bf09e1d69.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Compass Therapeutics, Inc. (CMPX)
CIK: 0001738021
Period of Report: 2025-02-11
Reporting Person: Anderman Jonathan (Sr VP, Gen Counsel & Corp Sec)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-11 | Stock Option (Right to Buy) | $3.65 | A | 280000 | Acquired | 2035-02-11 | Common Stock (280000) | Direct |
Footnotes
F1: The options vest over 48 substantially equal monthly installments starting March 11, 2025.
More from Compass Therapeutics, Inc.
Interim / Quarterly Report
2026
May 5
Regulatory Filings
2026
May 5
Annual Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 27
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Jan 12
Regulatory Filings
2026
Jan 8
Regulatory Filings
2026
Jan 6
Director's Dealing
2026
Jan 5